Combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Ph+ ALL. Dasatinib has significant clinical activity in patients with imatinib-resistance. We have examined the efficacy and safety of combining chemotherapy with dasatinib for patients with Ph+ ALL. Newly diagnosed patients receive dasatinib 50 mg po bid (or 100 mg daily) for the first 14 days of each of 8 cycles of alternating hyperCVAD and high dose cytarabine and methotrexate. Patients in complete remission (CR) receive maintenance daily dasatinib and monthly vincristine and prednisone for 2 years followed by dasatinib indefinitely. Thirty five patients with untreated Ph+ ALL with a median age of 53 years (range, 21 -79) were treated; 33 (94%) patients achieved CR.
INTRODUCTION
Prior to the introduction of tyrosine kinase inhibitors, the outcome of the majority of patients with Philadelphia-chromosome -positive (Ph+) acute lymphoblastic leukemia (ALL) was poor. Although complete remission (CR) could be achieved in most patients (60% -90%), CR duration and disease-free survival (DFS) were short with few long term survivors. In older patients particularly those older than 60 years of age, the outcome was particularly dismal with high treatment-related mortality, low CR rates and low long term DFS and survival. 1 As a result, allogeneic stem cell transplantation (allo SCT) would be offered to all patients with a suitable donor in first CR. Of interest, even with these traditional regimens, the degree of reduction of BCR-ABL transcripts after induction and consolidation was a powerful predictor of disease response and survival. 2 However, the success of allo SCT has been limited due to its associated toxicity and the limited availability of donors. The introduction of tyrosine kinase inhibitors improved the likelihood of identifying a donor as these agents provide relatively durable responses allowing for the identification of a donor. In vitro studies demonstrated synergistic or additive effects against Ph+ cell lines when imatinib was combined with various cytotoxic agents, suggesting a potential role for these combinations in patients. [3] [4] [5] Several investigators explored the efficacy of imatinib in combination with chemotherapy for frontline treatment of patients with Ph+ ALL. Initially the optimal schedule was debated and concurrent as well as sequential schedules were investigated. [6] [7] [8] [9] [10] [11] For personal use only. on January 2, 2018. by guest www.bloodjournal.org From
In the first clinical trial reporting the combination of imatinib with chemotherapy, a CR rate of 96% with a 2-year disease-free survival of 85% was reported and half of the initial cohort of 20 underwent allo SCT. 6 These were significantly superior to historical results using the chemotherapy regimen alone.
Furthermore, molecular complete responses as analyzed by reverse transcription polymerase chain reaction (RT-PCR) were reported in 60% of patients.
Importantly, there was no unexpected toxicity related to the addition of imatinib to the regimen. 6 Other investigators have also reported the results of studies incorporating imatinib into chemotherapy regimens designed for ALL and the initial debates of concurrent versus sequential imatinib have been largely settled by several reports of improved efficacy and low toxicity with the concurrent regimens. 9 In the early reports, the outcome of patients treated with such regimens was comparable whether the patients did or did not undergo an alloSCT in first CR, raising the debate of potential for "cure" without a transplant. 7, 11 Both acquired and intrinsic resistance to imatinib has been described in patients with Ph+ ALL. Acquired imatinib resistance may be due to BCR-ABLdependent mechanisms such as BCR-ABL overexpression or mutations in the kinase domains (KD). 12, 13 Other mechanisms of resistance independent of BCR-ABL have also been reported and include pharmacokinetic factors reducing the availability of imatinib within Ph+ cells, or activation of alternative signaling pathways such as the Src-kinase pathways. [14] [15] [16] For personal use only. on January 2, 2018. by guest www.bloodjournal.org From Second generation inhibitors capable of overcoming such resistance are available. Dasatinib is a dual Src and Abl kinase inhibitor that binds both active and inactive moieties of the bcr-abl protein and is approximately 325 times more potent against the kinase in preclinical studies. 17 The inhibition of Src may also be important in overcoming imatinib resistance particularly in lymphoid leukemias
where Src kinase activity may be important in their pathogenesis. 18 Dasatinib is active in vitro against all imatinib resistant BCR-ABL mutants with the exception of T315I. 17 Significant activity of dasatinib in patients with Ph+ leukemias who were resistant to or intolerant of imatinib has been reported. 19, 20 Ottmann et al conducted a phase II study of dasatinib in 36 patients with Ph+ ALL after failing imatinib. 20 The median age of the patients was 46 years (range, 15 to 85 years).
Major hematological response was achieved in 15 (42%) of patients and cytogenetic CR in 21 (58%). They reported 6 patients with a baseline T315I mutation, none of whom responded. Response rates were similar in patients with other mutations compared to those with no mutations. 20 Recently, administering dasatinib once daily in patients with Ph+ ALL produced similar responses and was associated with less toxicity with a lower incidence of myelosuppression or pleural effusions. 21 Based on the significant activity of dasatinib against BCR-ABL, and impressive data in patients with relapsed or imatinib-resistant disease, we hypothesized that the combination of dasatinib and chemotherapy would be effective in treating patients with Ph+ ALL and conducted this phase II study to examine the toxicity and efficacy of this regimen.
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PATIENTS AND METHODS

Eligibility
Patients with previously untreated Ph+ ALL [determined by the identification of either t(9;22) karyotype and/or BCR-ABL fusion transcript] were eligible. Furthermore, patients had to be 18 years or older, have an Eastern
Cooperative Group performance status of 2 or less, and have an adequate liver and renal function (with serum bilirubin ≤ 3.0 mg/dl, and a serum creatinine ≤ 3.0 mg/dl, unless considered due to tumor). Patients would be excluded if they had an active infection not controlled by antibiotics, clinical evidence of grade III-IV heart failure as defined by the New York Heart Association Criteria, active second malignancy, or prior history of treatment with dasatinib. Patients were also not eligible to participate if they were pregnant or breast feeding, had a history of bleeding diathesis, or a pleural or pericardial effusion thought not to be related to leukemia. All patients had to sign a consent form in accordance with the Declaration of Helsinki approved by the Institutional Review Board of the University of Texas -M D Anderson Cancer Center.
Treatment regimen
The details of the hyperCVAD regimen have been published previously. 6, 22 Odd courses (1, 3, 5, and 7) of hyperfractionated cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin), and dexamethasone were given alternately with even courses (2, 4, 6, and 8) of high dose cytarabine and methotrexate. All even courses were preceded by a chest X-ray to ensure the 
Minimal residual disease monitoring techniques
Molecular monitoring
BCR-ABL RQ-PCR was performed on total RNA extracted from leukocytes following red blood cell lysis. Reverse transcription was performed using random hexamers and PCR performed using TaqMan primer/probes for the e1a2, e13a2 (b2a2), and e14a2 (b3a2) BCR-ABL transcripts in a single tube with normalization to total ABL transcripts. Post-PCR capillary electrophoresis was used to type splice form, with the method having a sensitivity of approximately 1 in 10,000 BCR-ABL expressing cells as established by periodic dilution studies. 24 Major molecular response (MMR) was defined as a BCR-ABL/ABL ratio of less than 0.05%. BCR-ABL kinase domain (KD) mutation analysis covering codons 221 to 500 was performed on cDNA using a nested PCR strategy 25 For cases containing T315I mutation, quantitation of mutation levels was performed using a pyrosequencing-based strategy with a sensitivity of detection of 1%.
25
IGH clonality studies were performed on extracted genomic DNA using 
Multi-parameter flow cytometry
Minimal residual disease assessment by flow cytometry was performed on whole bone marrow specimens using a standard stain-lyse-wash procedure. 1 × 10 6 cells were stained per analysis tube, and data were acquired on 2 × 10 5 cells when specimen quality permitted. In the initial part of the study, data on fourcolor staining combinations were acquired on FACSCalibur cytometers using CellQuest software (BD Biosciences, San Diego, CA) and analyzed using FlowJo could be collected). We required aberrant expression of at least 2 antigens to make a diagnosis of MRD.
Response and outcome definitions
Complete response (CR) was defined as the presence of less than 5% blasts in the bone marrow (BM) with more than 1x10 9 /L neutrophils and more than 100x10 9 /L platelets in the peripheral blood (PB) with no extramedullary disease. Relapse was defined by recurrence of more than 5% blasts in a BM aspirate unrelated to recovery or by the presence of extramedullary disease. CR duration (CRD) was calculated from the time of CR until relapse. Disease-free survival (DFS) was calculated from the time of CR until relapse or death from any cause. Event-free survival (EFS) was calculated from the beginning of treatment until an event including relapse, death during induction or death in CR. Overall survival (OS) was calculated from the time of diagnosis until death.
Statistical methods
Survival curves were plotted by the Kaplan-Meier method and compared using the log-rank test. Differences in subgroups by different covariates were evaluated using the chi-square test for nominal values, and the Mann-Whitney U and Fischer's exact test for continuous variables. 
RESULTS
Patients and treatment
Response to induction
All but 2 patients are evaluable for assessment of response to induction (Table 2) . Thirty-three (94%) achieved CR after first course; two patients (6 %) died before response assessment from infections; in both patients, bone morrow exam on day 14 showed no detectable disease. The median time to achieving Three patients were taken off study for reasons other than death, transplant, or relapse. Two were taken off due to toxicity and commenced on Imatinib. In one patient the leukemic blasts were CD 20+ and rituximab was added to his therapy.
Toxicity
The median time to neutrophil and platelet recovery for cycle 1 was 18 and 23 days. The median time to platelet and neutrophil recovery for subsequent courses was 20 and 15 days (ranges, 0-37 and 0-35 days, respectively). Toxicity has included 16 episodes of bleeding (11 GI, 2 GU, 1 soft tissue hematoma and 2 subdural hematomas), and 8 episodes of pleural effusions. These include 2 episodes in the induction cycle and 6 in the subsequent cycles in 8 different patients; 6 episodes were of grade I/II severity and 2 of grade III/IV severity ( During induction and consolidation courses, all patients received dasatinib at the prescribed 100 mg daily; 2 patients received a reduced dose of dasatinib (70 mg daily) for 3 days while having an infection. At maintenance, 22 patients started dasatinib at 100mg daily and one at 50 mg daily. Of the 22, 14 remained on 100mg daily, and 7 were dose reduced (4 to 70mg daily, 2 to 50mg daily, and 1 to 50mg qod), one patient's dose was increased to 140mg daily due to an increasing PCR value for BCR-ABL. The reasons for dose reduction were cytopenias, pleural effusions, diarrhea, elevation of ALT, pericardial effusion, worsening renal function, and infections.
DISCUSSION
Several recent reports have better defined the outcome of patients with
Ph+ ALL who underwent an allogeneic stem cell transplant in the pre-imatinib era. 28 Mutations in the kinase domain of BCR-ABL have been reported to be an important mechanism of resistance to imatinib and their role in primary resistance and relapse in patients with ALL receiving the imatinib containing regimens is becoming clearer. 25, [31] [32] [33] Whether these mutations exist prior to the initiation of therapy or develop as a result of treatment-related clonal selection remains unclear. 25, 32 Early studies of patients with advanced Ph+ lymphoid leukemias identified KD mutations in most patients with acquired imatinib resistance.
However, KD mutations occurring prior to initiation of therapy with imatinib and accounting for primary resistance were not identified. 34 More recently, using more sensitive techniques, the presence of low-level KD mutations in imatinib-naïve patients have been reported. 32 The frequency of the mutant allele at the time of diagnosis was always below the level of detection by direct cDNA sequencing and ATP-binding P-loop mutations were the dominant type accounting for 83% of the mutations with the other 17% being T315I. 32 Remarkably, pre-existence of mutations including T315I did not adversely affect the CR rate or the achievement of molecular CR when compared with patients who only had unmutated BCR-ABL at diagnosis. 32 However, other investigators were unable to detect such pre-existing mutations in their cohort. 25 It is clear, however, that such mutations occur commonly in relapse. This was further confirmed in the current study where the majority of patients in relapse had mutations, including T315I.
Dasatinib is a more potent inhibitor of the tyrosine kinase activity of BCR-ABL in vitro and overcomes the majority of BCR-ABL resistance mutations. 17 Furthermore, phase II trials have demonstrated significant activity of dasatinib in patients with Ph+ ALL who have failed prior imatinib. 20 We, therefore, hypothesized that addition of dasatinib to chemotherapy may be more effective in maintaining responses than imatinib. Due to the concern for myelosuppression, we opted to give dasatinib 50 mg twice daily and only for 14 days each cycle to allow for the recovery of blood counts. With the release of data on enhanced safety and equivalent efficacy of once daily dosing, the protocol was amended and all subsequent patients received a once daily dose of 100 mg with chemotherapy and during maintenance. 21, 35 Overall, the regimen was well-tolerated although grade 3 and 4 side effects including several bleeding episodes as well as pleural effusions requiring treatment with steroids or discontinuation of therapy did occur. Dasatinib has a reported deleterious effect on platelet function which is likely to be exacerbated by chemotherapy-induced thrombocytopenia. 36,37 Furthermore, we avoided the use of proton pump inhibitors during the administration of dasatinib for the concern of drug interactions. The incidence of other adverse events such as pleural effusions was not significantly higher than that reported in single agent studies of dasatinib in Ph+ ALL and advanced phase CML. 38 Furthermore, the combination of chemotherapy and dasatinib did not result in unacceptable
For personal use only. on January 2, 2018. by guest www.bloodjournal.org From myelossuppression with the median time to platelet and neutrophil recovery for the induction course being 23 and 18 days, respectively (ranges,18-44 and 14-22 days, respectively).The regimen was better tolerated after achieving CR with rapid recovery of blood counts and fewer grade 3 and 4 adverse events in the subsequent courses of therapy. The length of follow-up for the majority of patients on the study is limited; therefore, the extent of toxicities and particularly any toxicity related to prolonged therapy with dasatinib is not yet clear.
With a median follow-up of 14 months (range 4 -37 months), 26 (74%) patients are alive and 24 (69%) are leukemia free. This compares favorably with historical data using the hyperCVAD regimen without a tyrosine kinase inhibitor and is similar to our previous regimen of hyperCVAD plus imatinib (p=NS). 30 In this study, only 4 patients (10%) underwent an allogeneic stem cell transplant in first CR as compared with 16 of 53 (20%) of patients in the imatinib study.
Despite this, the outcomes appear comparable in the two trials. Furthermore, survival and EFS at 2 to 3 years are of similar magnitude as was reported for the MRC/ECOG trial and the City of Hope with patients undergoing transplantation in first CR (Figures 4a and b) .
The degree of reduction of disease burden at CR and with follow-up as measured by QT-PCR was superior for the dasatinib containing regimen than our historical cohorts (data not shown). Previous reports have suggested that achievement of molecular responses in patients with Ph+ ALL is associated with a superior outcome. 2 Therefore, using a regimen that is consistently associated with reduction of disease burden at remission and with follow-up may be . A CR rate of 100% after 57 days of therapy with an overall survival of 81% at 10 months was reported.
There were no induction deaths and only 2 patients discontinued therapy due to toxicity. At the time of report, 9 of 35 patients enrolled had relapsed after a median of 72 days after the end of induction. No data was provided on the postremission therapy received. The authors concluded that the use of chemotherapy for induction of older patients with Ph+ ALL is questionable. We evaluated the outcome of patients enrolled on this study by age, and as expected, the overall survival was superior for younger patients (Figure 4c and d) . It is arguable that older patients may benefit from a less intensive regimen but the ideal strategy remains to be defined.
In conclusion, we have demonstrated the feasibility of combining chemotherapy with dasatinib in patients with Ph+ ALL. The regimen is effective in achieving long-term leukemia free survival even without an allogeneic stem cell transplant in first CR. Other strategies including continuous dosing of dasatinib or the addition of monoclonal antibodies may help further improve the outcome. For personal use only. on January 2, 2018. by guest www.bloodjournal.org From 
Months from Start of Treatment Overall Survival Probability
